ResMed CEO Michael J. Farrell sells 4,991 shares

Q: How many RMD shares did Michael J. Farrell sell, and at what price?

Michael J. Farrell sold 4,991 ResMed common shares on October 7, 2026, at a weighted average price of $226.3349 per share. The sale was conducted under a Rule 10b5-1 plan adopted October 31, 2024. The trades were executed at prices ranging from $222.2135 to $227.581.

Q: How many RMD options did Michael J. Farrell exercise?

Michael J. Farrell exercised options covering 4,991 ResMed common shares on October 7, 2026, at an exercise price of $146.34 per share. The listed expiration date for the options was November 21, 2026.

Q: When did Michael J. Farrell's RMD options first become exercisable?

The options first became exercisable on November 11, 2020, and vested one-third per year.

The reported sale prices ranged from $222.2135 to $227.581 across multiple trades.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ResMed Chairman and CEO Michael J. Farrell exercised options for 4,991 common shares on October 7, 2026, at an exercise price of $146.34 per share, then sold 4,991 shares at a weighted average price of $226.3349 per share.

The reported transactions were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the exercise, the reported option balance was 4,993 options; an indirect holding of 2,090 common shares was reported through the Lisette and Michael Farrell Family Trust.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,991 shares ($399K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Farrell Michael J.

Role Chairman and CEO

Sold 4,991 shs ($1.13M)

Approx. gross sale proceeds $1.13M

Approx. exercise cost $730K

Approx. pre-tax spread $399K

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options ^{F1, F3}	4,991	$0.00	$0.00
Exercise	ResMed Common Stock ^F1	4,991	$146.34	$730K
Sale	ResMed Common Stock ^{F1, F2}	4,991	$226.3349	$1.13M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 4,993 contracts (Direct); ResMed Common Stock — 479,803 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (3)

F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2. This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3. Represents date options first become exercisable. Options vest 1/3 per year

Key Figures

Options exercised: 4,991 shares Exercise price: $146.34 per share Shares sold: 4,991 shares +4 more

7 metrics

Options exercised 4,991 shares October 7, 2026

Exercise price $146.34 per share Options exercised October 7, 2026

Shares sold 4,991 shares October 7, 2026

Weighted average sale price $226.3349 per share Sale on October 7, 2026

Sale price range $222.2135-$227.581 per share Multiple trades on October 7, 2026

Options following exercise 4,993 options Reported following the October 7, 2026 exercise

Indirect common-share holding 2,090 shares Lisette and Michael Farrell Family Trust

Key Terms

Rule 10b5-1 plan, weighted average sale price, first become exercisable, vest

4 terms

Rule 10b5-1 plan regulatory

"Rule 10b5-1 plan adopted October 31, 2024"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"reflects the weighted average sale price"

first become exercisable financial

"date options first become exercisable"

vest financial

"Options vest 1/3 per year"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RMD shares did Michael J. Farrell sell, and at what price?

Michael J. Farrell sold 4,991 ResMed common shares on October 7, 2026, at a weighted average price of $226.3349 per share. The sale was conducted under a Rule 10b5-1 plan adopted October 31, 2024. The trades were executed at prices ranging from $222.2135 to $227.581.

How many RMD options did Michael J. Farrell exercise?

Michael J. Farrell exercised options covering 4,991 ResMed common shares on October 7, 2026, at an exercise price of $146.34 per share. The listed expiration date for the options was November 21, 2026.

When did Michael J. Farrell's RMD options first become exercisable?

The options first became exercisable on November 11, 2020, and vested one-third per year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/08/2026 - 05:32 PM Accepted by SEC EDGAR 10/08/2026 - 05:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last)

(First)

(Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO

CALIFORNIA

92123

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	10/07/2026		M⁽¹⁾		4,991	A	$146.34	484,794	D
ResMed Common Stock	10/07/2026		S⁽¹⁾		4,991	D	$226.3349⁽²⁾	479,803	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock Options	$146.34	10/07/2026		M⁽¹⁾			4,991	11/11/2020⁽³⁾	11/21/2026	ResMed Common Stock	4,991	$0	4,993	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year

	/s/ Michael J. Farrell, Chairman and CEO	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR